Mini Gastric Bypass After GLP-1 Medications
Educational overview for patients who have used GLP-1 receptor agonists and are now researching bariatric surgery.
Why Some Patients Research Surgery After GLP-1 Therapy
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others — have helped many patients lose weight. Some patients reach a plateau, experience side effects, face access or cost challenges, or experience weight regain after discontinuation. Surgery becomes a topic some patients explore in this context.
Important: Do Not Change Medications Without Your Clinician
Decisions about starting, continuing, adjusting, or stopping GLP-1 medications must be made with the prescribing clinician. This website does not advise stopping any medication. Any peri-operative medication plan should be coordinated between your prescribing clinician and your surgical team.
What Surgeons Commonly Review for GLP-1 Patients
- Current GLP-1 medication, dose, and duration of use
- Weight trajectory on and off medication
- Diabetes status, HbA1c, and other diabetes medications
- Side effects experienced
- Gastrointestinal motility considerations (relevant to peri-operative planning)
- Nutritional status
How Bariatric Surgery and GLP-1 Therapy Differ
GLP-1 medications work through hormonal pathways and generally require ongoing use. Bariatric procedures including Mini Gastric Bypass create an anatomical change that supports long-term weight management. The two approaches are different in mechanism, reversibility, and long-term care requirements. Neither is universally right for every patient.
Combined Pathways
Some patients and clinical teams discuss combined or sequential approaches — for example, using GLP-1 therapy as part of pre-operative optimization, or considering surgery after a defined medication course. These pathways are individualized and require coordination across the prescribing clinician, surgical team, and patient.